Link to replay: https://channel.royalcast.com/landingpage/hegnarmedia/20210218_7/
Presentations
Targovax CMD 3_ONCOS-102 Development program
Targovax CMD 4_Immune Activation
Targovax CMD 5_Preclinical pipeline update
Targovax CMD 7_Closing remarks
Targovax ASA invites investors, analysts and media to a Capital Markets Day on Thursday 18 February 2021
Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.
DATE Thursday, February 18, 2021
TIME 2:30 PM CET
LOCATION Virtual event – live streaming
REPLAY Available after the event
REGISTER contact@targovax.com
The agenda will be as follows:
|
Agenda & speakers |
||
| 2:30-2:40 PM | Welcome | Øystein Soug, CEO, Targovax |
| 2:40-3:25 PM | Anti-PD1 refractory melanoma | Alexander N. Shoushtari, MD |
| 3:25-3:45 PM | ONCOS-102 development program | Magnus Jäderberg, CMO, Targovax |
|
5 minutes break |
||
| 3:50-4:05 PM | Immune activation | Victor Levitsky, CSO, Targovax |
| 4:05-4:15 PM | Preclinical pipeline update | Victor Levitsky, CSO, Targovax |
| 4:15-4:25 PM | 4Q update | Torbjørn Furuseth, CFO, Targovax |
| 4:25 PM | Closing remarks | Øystein Soug, CEO, Targovax |
The presentations will be made available on the company´s website after the end of the meeting. Questions can be submitted through the webcast throughout the event.
Biography:
Dr. Alexander Shoushtari is renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He is part of several immunotherapy trials at MSKCC and Dr. Alexander Shoushtari is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma.